<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="width: 44%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">January 23, 2012</TD>
    <TD STYLE="width: 28%; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Date of Report (Date of earliest event reported)</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bionovo, Inc.</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Exact Name of Registrant as Specified in Charter)</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 32%">Delaware</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 34%">001-33498</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 32%">20-5526892</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or Other</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Jurisdiction of Incorporation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 50%">5858 Horton Street, Suite 400, Emeryville, CA 94608</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Address of Principal Executive Offices)&nbsp; (Zip Code)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(510) 601-2000</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Registrant's telephone number, including area code)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: justify; text-indent: -30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: justify; text-indent: -30pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: justify; text-indent: -30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: justify; text-indent: -30pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-weight: bold">Item 3.01.</TD>
    <TD STYLE="width: 88%; font-weight: bold"><B>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As discussed in the press release attached hereto
as Exhibit 99.1, on January 27, 2012, Bionovo, Inc. (the &ldquo;<U>Company</U>&rdquo;) notified The NASDAQ Stock Market, Inc. (&ldquo;<U>NASDAQ</U>&rdquo;)
of the Company&rsquo;s determination to file a Form 25 with the U.S. Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;)
to effect the voluntary delisting of its common stock from the NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Despite having until March 10, 2012 to regain
compliance with NASDAQ&rsquo;s continued listing requirement under Listing Rule 5550, the Company&rsquo;s Board of Directors on
January 26, 2012 determined that it is in the best interest of the Company to voluntarily delist its common stock from the NASDAQ
Capital Market. The Company plans to file the Form 25 with the SEC on or about February 7, 2012. The Company intends to continue
to file reports pursuant to the requirements of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">It is expected that the delisting will take
effect as of the close of trading in New York on February 17, 2012 and the Company is making arrangements for its common stock
to thereafter be quoted on the Over-The-Counter Bulletin Board. The Over-The-Counter Bulletin Board is a market tier for over-the-counter-traded
companies that are registered and reporting with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-size: 10pt; font-weight: bold">Item 5.02.</TD>
    <TD STYLE="width: 88%; font-size: 10pt; font-weight: bold">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each of Isaac Cohen, the Company&rsquo;s
Chairman, Chief Executive Officer, Chief Scientific Officer and a member of the Board of Director, and Mary Tagliaferri, the
Company&rsquo;s President, Chief Medical Officer, Chief Regulatory Officer, Secretary, Treasurer and a member of the Board of
Director (together, the &ldquo;<U>Executives</U>&rdquo;)entered into amended and restated employment agreements (the
&ldquo;<U>Employment Agreements</U>&rdquo;) with the Company, effective January 23, 2012. Pursuant to the Employment
Agreements each Executive receives a base annual salary of $375,000 and an annual bonus, the amount of which shall
be determined by the Company&rsquo;s Compensation Committee and or the Board of Directors in their discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Dr. Cohen&rsquo;s Employment Agreement provides
that, in the event of termination of employment by Dr. Cohen for &ldquo;good reason,&rdquo; or a termination of employment by the
Company without &ldquo;cause&rdquo;, change in control or non renewal, as such terms are defined in such Employment Agreement,
Dr. Cohen shall be entitled to receive: (a) a lump sum in an amount equal to two and one-half years of Dr. Cohen&rsquo;s base annual
salary; (b) a lump sum in an amount equal to the annual bonus paid by the Company to Dr. Cohen for the last fiscal year of the
Company ending prior to the date of termination multiplied by two and one-half; (c) insurance coverage for Dr. Cohen and his dependents,
at the same level and at the same charges to Dr. Cohen as immediately prior to his termination, for a period of two and one-half
years following his termination from the Company; (d) all accrued obligations, as defined therein; and (e) with respect to each
incentive pay plan (other than stock option or other equity plans) of the Company in which Dr. Cohen participated at the time of
termination, an amount equal to the amount Dr. Cohen would have earned if he had continued employment for two and one-half additional
years. If Dr. Cohen is terminated by reason of his disability, he shall be entitled to receive, for two and one-half years after
such termination, his base annual salary less any amounts received under a long term disability plan. If Dr. Cohen&rsquo;s employment
with the Company is terminated by reason of his death, his legal representatives shall receive the balance of any remuneration
due him under the terms of his Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Dr. Tagliaferri&rsquo;s Employment Agreement
provides that, in the event of termination of employment by Dr. Tagliaferri for &ldquo;good reason,&rdquo; or a termination of
employment by the Company without &ldquo;cause&rdquo;, change in control or non renewal, as such terms are defined in such Employment
Agreement, Dr. Tagliaferri shall be entitled to receive: (a) a lump sum in an amount equal to two and one-quarter years of Dr.
Tagliaferri&rsquo;s base annual salary; (b) a lump sum in an amount equal to the annual bonus paid by the Company to Dr. Tagliaferri
for the last fiscal year of the Company ending prior to the date of termination multiplied by two and one-quarter; (c) insurance
coverage for Dr. Tagliaferri and her dependents, at the same level and at the same charges to Dr. Tagliaferri as immediately prior
to her termination, for a period of two and one-quarter years following her termination from the Company; (d) all accrued obligations,
as defined therein; and (e) with respect to each incentive pay plan (other than stock option or other equity plans) of the Company
in which Dr. Tagliaferri participated at the time of termination, an amount equal to the amount Dr. Tagliaferri would have earned
if he had continued employment for two and one-quarter additional years. If Dr. Tagliaferri is terminated by reason of her disability,
he shall be entitled to receive, for two and one-quarter years after such termination, her base annual salary less any amounts
received under a long term disability plan. If Dr. Tagliaferri&rsquo;s employment with the Company is terminated by reason of her
death, her legal representatives shall receive the balance of any remuneration due him under the terms of her Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each of the Employment Agreements currently
expires on January 23, 2017, but will automatically renew for successive two year periods unless notice is given to the Company
within 180 days of the end of such successive term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The above descriptions of the Employment Agreements
are summaries and are qualified in their entirety by reference to Dr. Cohen&rsquo;s Employment Agreement filed herewith as Exhibit
10.1 and incorporated herein by reference and Dr. Tagliaferri&rsquo;s Employment Agreement filed herewith as Exhibit 10.2 and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-size: 10pt; font-weight: bold">Item 9.01.</TD>
    <TD STYLE="width: 88%; font-size: 10pt; font-weight: bold">Financial Statements and Exhibits.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: justify">(d)</TD>
    <TD STYLE="width: 88%; font-size: 10pt; font-style: italic; text-align: justify">Exhibits.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: justify">Exhibit</TD>
    <TD STYLE="width: 85%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; text-align: justify">Number</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">10.1</TD>
    <TD STYLE="text-align: justify">Amended and Restated Employment Agreement between Bionovo, Inc. and Isaac Cohen, dated as of January 23, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">10.2</TD>
    <TD STYLE="text-align: justify">Amended and Restated Employment Agreement between Bionovo, Inc. and Mary Tagliaferri, dated as of January 23, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">99.1</TD>
    <TD STYLE="text-align: justify">Bionovo, Inc. Press Release dated January 27, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Bionovo, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 51%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date:&nbsp; January 27, 2012</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp; /s/ Isaac Cohen</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Isaac Cohen</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">10.1</TD>
    <TD STYLE="width: 93%; text-align: justify">Amended and Restated Employment Agreement between Bionovo, Inc. and Isaac Cohen, dated as of January 23, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.2</TD>
    <TD STYLE="text-align: justify">Amended and Restated Employment Agreement between Bionovo, Inc. and Mary Tagliaferri, dated as of January 23, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">99.1</TD>
    <TD STYLE="text-align: justify">Bionovo, Inc. Press Release dated January 27, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v300638_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 25172}]
{"company-data": {"conformed-name": "BIONOVO INC", "cik": "0001203957", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33498", "film-number": "12552856"}, "business-address": {"street1": "5858 HORTON STREET", "street2": "SUITE 400", "city": "EMERYVILLE", "state": "CA", "zip": "94608", "phone": "510-601-2000"}, "mail-address": {"street1": "5858 HORTON STREET", "street2": "SUITE 400", "city": "EMERYVILLE", "state": "CA", "zip": "94608"}, "former-company": [{"former-conformed-name": "BIONOVO", "date-changed": "20051222"}, {"former-conformed-name": "BioMETRX (formerly MarketShare)", "date-changed": "20051118"}, {"former-conformed-name": "BIONOVO, INC.", "date-changed": "20050630"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
January 23, 2012
Date of Report (Date of earliest event reported)
Bionovo, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-33498
20-5526892
(State or Other
(Commission File Number)
(IRS Employer
Jurisdiction of Incorporation)
Identification No.)
5858 Horton Street, Suite 400, Emeryville, CA 94608
(Address of Principal Executive Offices)  (Zip Code)
(510) 601-2000
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As discussed in the press release attached hereto
as Exhibit 99.1, on January 27, 2012, Bionovo, Inc. (the "
Company
") notified The NASDAQ Stock Market, Inc. ("
NASDAQ
")
of the Company's determination to file a Form 25 with the U.S. Securities and Exchange Commission ("
SEC
")
to effect the voluntary delisting of its common stock from the NASDAQ Capital Market.
Despite having until March 10, 2012 to regain
compliance with NASDAQ's continued listing requirement under Listing Rule 5550, the Company's Board of Directors on
January 26, 2012 determined that it is in the best interest of the Company to voluntarily delist its common stock from the NASDAQ
Capital Market. The Company plans to file the Form 25 with the SEC on or about February 7, 2012. The Company intends to continue
to file reports pursuant to the requirements of the Securities Exchange Act of 1934, as amended.
It is expected that the delisting will take
effect as of the close of trading in New York on February 17, 2012 and the Company is making arrangements for its common stock
to thereafter be quoted on the Over-The-Counter Bulletin Board. The Over-The-Counter Bulletin Board is a market tier for over-the-counter-traded
companies that are registered and reporting with the SEC.
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Each of Isaac Cohen, the Company's
Chairman, Chief Executive Officer, Chief Scientific Officer and a member of the Board of Director, and Mary Tagliaferri, the
Company's President, Chief Medical Officer, Chief Regulatory Officer, Secretary, Treasurer and a member of the Board of
Director (together, the "
Executives
")entered into amended and restated employment agreements (the
"
Employment Agreements
") with the Company, effective January 23, 2012. Pursuant to the Employment
Agreements each Executive receives a base annual salary of $375,000 and an annual bonus, the amount of which shall
be determined by the Company's Compensation Committee and or the Board of Directors in their discretion.
Dr. Cohen's Employment Agreement provides
that, in the event of termination of employment by Dr. Cohen for "good reason," or a termination of employment by the
Company without "cause", change in control or non renewal, as such terms are defined in such Employment Agreement,
Dr. Cohen shall be entitled to receive: (a) a lump sum in an amount equal to two and one-half years of Dr. Cohen's base annual
salary; (b) a lump sum in an amount equal to the annual bonus paid by the Company to Dr. Cohen for the last fiscal year of the
Company ending prior to the date of termination multiplied by two and one-half; (c) insurance coverage for Dr. Cohen and his dependents,
at the same level and at the same charges to Dr. Cohen as immediately prior to his termination, for a period of two and one-half
years following his termination from the Company; (d) all accrued obligations, as defined therein; and (e) with respect to each
incentive pay plan (other than stock option or other equity plans) of the Company in which Dr. Cohen participated at the time of
termination, an amount equal to the amount Dr. Cohen would have earned if he had continued employment for two and one-half additional
years. If Dr. Cohen is terminated by reason of his disability, he shall be entitled to receive, for two and one-half years after
such termination, his base annual salary less any amounts received under a long term disability plan. If Dr. Cohen's employment
with the Company is terminated by reason of his death, his legal representatives shall receive the balance of any remuneration
due him under the terms of his Employment Agreement.
1
Dr. Tagliaferri's Employment Agreement
provides that, in the event of termination of employment by Dr. Tagliaferri for "good reason," or a termination of
employment by the Company without "cause", change in control or non renewal, as such terms are defined in such Employment
Agreement, Dr. Tagliaferri shall be entitled to receive: (a) a lump sum in an amount equal to two and one-quarter years of Dr.
Tagliaferri's base annual salary; (b) a lump sum in an amount equal to the annual bonus paid by the Company to Dr. Tagliaferri
for the last fiscal year of the Company ending prior to the date of termination multiplied by two and one-quarter; (c) insurance
coverage for Dr. Tagliaferri and her dependents, at the same level and at the same charges to Dr. Tagliaferri as immediately prior
to her termination, for a period of two and one-quarter years following her termination from the Company; (d) all accrued obligations,
as defined therein; and (e) with respect to each incentive pay plan (other than stock option or other equity plans) of the Company
in which Dr. Tagliaferri participated at the time of termination, an amount equal to the amount Dr. Tagliaferri would have earned
if he had continued employment for two and one-quarter additional years. If Dr. Tagliaferri is terminated by reason of her disability,
he shall be entitled to receive, for two and one-quarter years after such termination, her base annual salary less any amounts
received under a long term disability plan. If Dr. Tagliaferri's employment with the Company is terminated by reason of her
death, her legal representatives shall receive the balance of any remuneration due him under the terms of her Employment Agreement.
Each of the Employment Agreements currently
expires on January 23, 2017, but will automatically renew for successive two year periods unless notice is given to the Company
within 180 days of the end of such successive term.
The above descriptions of the Employment Agreements
are summaries and are qualified in their entirety by reference to Dr. Cohen's Employment Agreement filed herewith as Exhibit
10.1 and incorporated herein by reference and Dr. Tagliaferri's Employment Agreement filed herewith as Exhibit 10.2 and incorporated
herein by reference.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number
10.1
Amended and Restated Employment Agreement between Bionovo, Inc. and Isaac Cohen, dated as of January 23, 2012.
10.2
Amended and Restated Employment Agreement between Bionovo, Inc. and Mary Tagliaferri, dated as of January 23, 2012.
99.1
Bionovo, Inc. Press Release dated January 27, 2012.
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Bionovo, Inc.
Date:  January 27, 2012
By:
/s/ Isaac Cohen
Isaac Cohen
Chairman and Chief Executive Officer
3
EXHIBIT INDEX
10.1
Amended and Restated Employment Agreement between Bionovo, Inc. and Isaac Cohen, dated as of January 23, 2012.
10.2
Amended and Restated Employment Agreement between Bionovo, Inc. and Mary Tagliaferri, dated as of January 23, 2012.
99.1
Bionovo, Inc. Press Release dated January 27, 2012.